The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

Insmed Incorporated INSM announced that the FDA has accepted its new drug application (“NDA”) seeking approval of its ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...

Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.

The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...

The phase 3 trial achieved a statistically significant reduction in the frequency of exacerbations in patients with bronchiectasis, a serious, chronic lung disease with no approved treatment that ...

interstitial lung disease, bronchiectasis, benign and malignant neoplasms, and lung transplantation. The Lung Institute has developed a comprehensive program across specialties with one site for ...

THE chairman of lung disease charity Lungevity is looking to increase awareness of its services and outreach, as it ...

Macrolide maintenance therapy in patients with bronchiectasis significantly reduces the risk for major adverse cardiovascular events.

Baylor Medicine’s Interstitial Lung Disease (ILD) program offers specialized and multidisciplinary care. We bring together a unique team of physicians of multiple sub-specialties for patients with a ...